Part 1 of 4 of an interview with French professor, Christian Perronne. We hear about HCQ protocols, Ivermectin protocols, and also for the first time—at least for me—a clear explanation of the “Covid19 long haulers” mystery. If I got that right (I might have missed a few words when listening to French-accented English at 2x speed), what’s happening to long haulers is actually nothing new: some infections may lock a person’s immune system into a “poor state”, which means they start getting symptoms from a variety of germs and pathogens that are normally present in the environment and in a person’s body, but that would normally be kept in check by a healthy immune system. In essence, it’s a form of immunodeficiency that’s causing the long-lasting symptoms.
A bio for Dr Perronne in English.
Also, from the interviewer:
Professor Perronne has a long distinguished career in medicine. He was vice-chairman of the National Reference Centre on Tuberculosis and Mycobacteria at the Pasteur Institute in Paris. He is the past-president of the French College of Professors of Infectious and Tropical Diseases (CMIT). He was president of the Communicable diseases commission at France’s High Council for Public Health (HCSP), an official body making recommendations for public health and vaccination policies.
Since 1994, Professor Christian Perronne has been a leader in the the development of therapies for chronic Lyme disease, which brought him, well before COVID-19, to already challenge the medical establishment about how to treat this disease.
Professor Perronne has also considerable expertise with vaccination, as he is a past vice-president of the European Advisory Group of Experts on Immunisation – an official body advising the World Health Organization.
Professor Perronne was in the heat of the COVID-19 pandemic, as chief of a department of infectious diseases at the Raymond Poincaré University Hospital in Garches, belonging to the Greater Paris University Hospitals group. He used the therapeutic protocol developed in Marseille by Professor Raoult and his team, comprising hydroxychloroquine and azithromycin.